Of the substances mentioned, MDMA is potentially hepatotoxic (toxic to the liver), particularly at high doses or with frequent use. LSD and psilocybin are not hepatotoxic and do not usually cause liver damage. MDMA is therefore the most harmful to the liver of these three substances.

Detailed explanation:

MDMA (3,4-methylenedioxymethamphetamine) has been shown to have hepatotoxic effects, particularly when taken in high doses or frequently. The risk also increases significantly when MDMA is combined with alcohol or other substances that put a strain on the liver. Liver damage caused by MDMA can range from elevated liver enzymes – a sign of liver stress – to severe acute hepatitis and, in extreme cases, even liver failure.

The reason why MDMA is hepatotoxic lies in the metabolism of MDMA. When MDMA is broken down in the liver, toxic metabolites such as catechol metabolites are produced, which can be harmful to liver cells. This risk is particularly heightened when MDMA is taken in combination with other drugs such as alcohol, cocaine or certain medicines. Symptoms that may indicate MDMA-related liver damage include nausea, abdominal pain, jaundice (yellowing of the skin or eyes), fatigue, dark urine and pale-coloured stools.

Psilocybin (from magic mushrooms) By contrast, it has no known hepatotoxic effect. There is virtually no evidence from scientific research to suggest that psilocybin causes liver damage at standard recreational or therapeutic doses. Psilocybin is rapidly converted into psilocin in the body and is subsequently excreted via the kidneys. Consequently, there are no known significant cases of liver failure resulting solely from the use of psilocybin.

Also LSD (lysergic acid diethylamide) is considered non-hepatotoxic and has a very favourable safety profile with regard to liver health. Although LSD is broken down by the liver, this process does not produce any toxic metabolites that cause damage to the liver. Even at relatively high doses, there are hardly any documented cases of LSD-related liver damage. LSD generally has very low physical toxicity.

When we look at the relative hepatotoxicity of these substances, we can see that MDMA is clearly at the top of the list, whilst psilocybin and LSD are both non-hepatotoxic.

Advice on minimising harm from MDMA use:

If you choose to take MDMA, it is important to take steps that can significantly reduce the risk of liver damage. Firstly, it is important to keep doses low, preferably no more than 1–1.5 mg per kilogram of body weight. Allow yourself plenty of time to recover and take a break of at least three months between each use. It is essential never to combine MDMA with other substances that put a strain on the liver, such as alcohol, cocaine or certain medicines, including paracetamol and some antibiotics.

It is also important to drink enough (but not too much) water to prevent dehydration and ensure that your body does not overheat, as this can put additional strain on the liver. A healthy lifestyle around your use also helps: avoid alcohol before and after taking MDMA, eat a healthy diet and support your liver with antioxidants such as vitamin C, N-acetylcysteine (NAC), milk thistle and glutathione.

Natural remedies and Herbs can help support your liver health. Well-known herbs that support liver function include, for example, garlic (Allium sativum), sickle-leaved golden-screen (Bupleurum falcatum), Javanese turmeric root (Curcuma xanthorrhiza), artichoke (Cynara scolymus), Picrorhiza kurroa, black radish (Raphanus sativus niger), rosemary (Rosmarinus officinalis), milk thistle (Silybum marianum) and dandelion (Taraxacum officinale).

Finally, it is advisable to have your liver function checked regularly, particularly if you use MDMA frequently. This allows you to identify any potential damage at an early stage and prevent it from getting worse.

Conclusion:

In summary, MDMA carries clear risks of liver damage, particularly when used incorrectly or in excess. Psilocybin and LSD pose minimal to no risk to the liver. By using MDMA responsibly and taking the precautions mentioned, you can effectively minimise these risks.

When it comes to liver toxicity (hepatotoxicity) associated with MDMA, psilocybin and LSD, there are clear differences in risk between these substances. Based on clinical experience and available real-world data, the following picture emerges:

MDMA (Ecstasy) poses the greatest risk of liver damage. The substance is metabolised in the liver via the enzyme CYP2D6. During this process, reactive metabolites may be formed which damage liver cells. In rare cases, serious conditions such as hepatitis, liver necrosis or acute liver failure have been reported, particularly with high doses, repeated use or a genetic predisposition to slow metabolism of the substance. The risk also increases with poly-drug use or poor hydration.

Psilocybin, the active ingredient in magic mushrooms and truffles, is converted in the body into psilocin, which is relatively gentle on the liver. There is no convincing evidence that psilocybin is harmful to the liver at normal or therapeutic doses. Clinical studies also show no significant strain on the liver, meaning the risk is considered to be very low to negligible.

LSD (lysergic acid diethylamide) is also metabolised by the liver, but without any clear evidence of hepatotoxicity. The risk is considered to be low, although long-term or intensive use has not yet been extensively studied.

If you want to give your liver extra protection when taking psychedelics, it is important to drink plenty of fluids, avoid extreme temperatures, not to combine them with other toxic substances such as alcohol or paracetamol, and always start with a low dose.

MDMA (ecstasy) and liver toxicity

MDMA is a synthetic amphetamine that is extensively metabolised in the liver. Several studies and case reports show that MDMA can cause acute liver failure. For example, Andreu et al. (1998) reported that ecstasy caused 5 out of 62 cases of acute liver failure (8%) in their cohort – accounting for 31% of all drug-induced liver failure cases. In patients under the age of 25, ecstasy was even the second most common cause of liver damage (20% of all cases, 36% after excluding viral causes). Clinical case reports describe extremely high liver enzyme levels (AST and ALT up to 40–70× the normal range) following the ingestion of high doses of MDMA. One example is a 23-year-old who developed acute hepatitis after doubling his intake (AST 1423 U/L, ALT 2748 U/L). In all reported cases, patients made a full recovery within a few weeks to months.

• Epidemiology and case studies: Several reports confirm MDMA-related hepatitis. In addition to Andreu et al. (1998), later case reports demonstrate recurrent toxic hepatitis following repeated use. For example, a chronic MDMA user developed liver failure again following a single high dose. A large review even reported a patient who was admitted for a liver transplant following MDMA use (Dooley et al. 2019).
• Mechanisms: MDMA is metabolised in the liver via CYP2D6 (and, to a lesser extent, CYP1A2/3A4) into active and harmful metabolites. Reactive quinone metabolites can cause oxidative stress and mitochondrial damage. In addition, MDMA-induced hyperthermia, dehydration and disseminated intravascular coagulation (DIC) contribute to liver cell necrosis. Animal studies and reviews emphasise that this combination of increased ROS production due to metabolism and vasodilation in the liver can lead to fulminant liver failure.
• Occasional vs chronic use: Even a single high dose of MDMA can cause serious liver damage. Recurrent episodes have been reported following repeated use or higher doses (unintentional “double-dipping”). In the case mentioned above, hepatitis occurred twice, each time following a double dose. Chronic MDMA use appears to increase the risk of damage, particularly when combined with other substances. An analysis of regulatory data (FAERS) showed that, of 23 reports of MDMA-associated liver damage, 22 cases involved one or more other known hepatotoxic substances; only one report identified MDMA as the primary suspected substance (along with alcohol). Occasional use on its own therefore appears to lead to liver failure much less frequently than use in combination with other substances.
• Frequency and outcome: Although MDMA-induced acute hepatitis can be severe (even life-threatening), all reported patients in the available case series have recovered within a few weeks to months. Nevertheless, the literature emphasises that young patients with unexplained acute liver failure should always be asked about ecstasy use.

Psilocybin (magic mushrooms) and liver toxicity

Psilocybin is a psychedelic substance found in “magic mushrooms” and is rapidly converted into psilocin in the body. Psilocybin/psilocin is primarily broken down via glucuronidation and does not produce any known reactive or toxic liver metabolites. No cases of liver toxicity caused by psilocybin itself have been described in the literature. The Utah Poison Control Centre explicitly states: “Magic mushrooms do not cause liver damage”. All rare cases of acute liver failure following mushroom poisoning appear to be caused by amatoxins (for example, from Amanita species), not by psilocybin.

• Metabolism and safety: Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is rapidly dephosphorylated in the gastrointestinal tract to form the active compound psilocin, which is broken down by enzymes such as monoamine oxidase and UGTs into inactive metabolites. In vitro, ~30% appears to be metabolised by human liver microsomes, largely without toxicity.
• Clinical data: No significant liver function abnormalities have been reported in controlled clinical trials of psilocybin for depression and anxiety. Overall, only mild, short-lived side effects such as nausea or headaches have been reported during sessions involving pure psilocybin. There is no epidemiological or clinical evidence that recreational use of psilocybin causes liver disease. Preclinical research even suggests a positive effect: low doses of psilocybin reduced hepatic steatosis and improved metabolic parameters in animal models【66†】 (sufficient evidence for this is still lacking in the literature, but it underlines the absence of acute toxic effects).
• Occasional vs chronic use: The difference between single and repeated use of psilocybin appears to be negligible for the liver. Psilocybin is not stored in fatty tissue and does not accumulate; tolerance to the psychedelic effects does develop, but there are no reports of liver toxicity. As long as the mushrooms reliably contain psilocybin (without amatoxins), the risk of liver toxicity is virtually nil.

LSD (lysergic acid diethylamide) and liver toxicity

LSD is known for its powerful psychoactive effects, but physiologically it is relatively safe. LSD is metabolised in the liver (including by CYP enzymes), but this does not produce any toxic intermediate metabolites. StatPearls (2023) explicitly states that No deaths due to direct LSD toxicity have been reported at normal doses. At normal therapeutic or recreational doses (50–200 µg), LSD does not cause any demonstrable organ damage.

• Clinical experiences: No cases of LSD-induced hepatitis or liver failure have been described in the literature. A recent retrospective study of LSD- and psilocybin-related deaths (Darke et al. 2024) indicated that most fatal incidents among LSD users were related to accidents or poly-drug use, rather than direct organ damage. In only one reported case was LSD cited as the sole cause, but there is no evidence that this involved liver failure.
• Mechanism and metabolism: LSD is rapidly converted into inactive metabolites (such as 2-oxo-3-hydroxy-LSD) and has a short half-life (~3 hours). There is no mechanistic evidence that LSD itself causes damage to liver cells. Theoretically, very high doses of LSD (or intravenous use, see LSD “mainlining” c. 1967) could indirectly cause liver stress (via convulsions or vascular reactions), but such situations are outside the scope of normal use and are extremely rare.
• Occasional vs chronic use: LSD leads to rapid tolerance to its behavioural effects, but is also rapidly metabolised. There is no evidence that chronic, repeated use at normal doses leads to liver toxicity. The risk therefore remains low regardless of the pattern of use.

Conclusion

Based on current knowledge, MDMA is by far the substance most commonly associated with liver toxicity. Several studies have linked MDMA use to severe acute hepatitis and liver failure, particularly at high doses or in combination with other hepatotoxic substances. Figures from the literature emphasise this: in one series, ecstasy was implicated in 31% of all drug-induced cases of liver failure in young people. In contrast, there are no similar reports of LSD- or psilocybin-induced hepatitis. Psilocybin (magic mushrooms) contains no liver toxins and – apart from cases of mistaken ingestion of poisonous mushrooms – does not cause liver damage. LSD appears to be virtually non-toxic physiologically; no deaths or cases of liver failure have been directly attributed to LSD at normal doses.

In summary: of the three substances, MDMA places the greatest strain on the liver, particularly in cases of intoxication or cumulative use. LSD and psilocybin appear to be safe under recreational and clinical use safe for the liver . Whilst the literature on MDMA reports acute hepatitis, elevated transaminases and even liver failure, there is no such evidence for LSD or psilocybin. For MDMA, the distinction between occasional and chronic use is significant: higher or repeated doses increase the risk of recurrent liver damage. No such difference is known to exist for LSD or psilocybin.

Sources: Andreu et al. (1998); Onur et al. (2008); Makunts et al. (2024); Thomann et al. (2024); Utah Poison Control Centre (2024); StatPearls (2023); Darke et al. (2024).